Nozomi Niitsu

Summary

Affiliation: Kitasato University
Country: Japan

Publications

  1. ncbi Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa 228 8555, Japan
    Clin Cancer Res 11:697-702. 2005
  2. ncbi Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma
    N Niitsu
    First Department of Internal Medicine, Toho University School of Medicine, Tokyo Research Institute, Saitama Cancer Center, Saitama
    Blood 97:1202-10. 2001
  3. ncbi Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Br J Haematol 123:621-30. 2003
  4. ncbi Primary gastric T-cell lymphoma not associated with human T-lymphotropic virus type I: a case report and review of the literature
    N Niitsu
    Department of Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Ann Hematol 82:197-202. 2003
  5. ncbi Ovarian follicular lymphoma: a case report and review of the literature
    Nozomi Niitsu
    Department of Internal Medicine IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa, 228 8555, Japan
    Ann Hematol 81:654-8. 2002
  6. ncbi The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukem
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Exp Hematol 30:1273-82. 2002
  7. ncbi Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-gamma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa 228 8555, Japan
    Leuk Res 26:745-55. 2002
  8. ncbi Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Eur J Haematol 68:91-100. 2002
  9. ncbi High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine, Internal Medicin IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa 228 8555, Japan
    Leuk Res 26:241-8. 2002
  10. ncbi Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study
    N Niitsu
    Department of Hematology and Internal Medicine IV, School of Medicine, Kitasato University, Japan
    Ann Hematol 80:602-6. 2001

Collaborators

Detail Information

Publications49

  1. ncbi Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa 228 8555, Japan
    Clin Cancer Res 11:697-702. 2005
    ..Doxorubicin is often given during the initial treatment. The dosage or drugs chosen for salvage therapy are limited by doxorubicin-induced cardiomyopathy...
  2. ncbi Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma
    N Niitsu
    First Department of Internal Medicine, Toho University School of Medicine, Tokyo Research Institute, Saitama Cancer Center, Saitama
    Blood 97:1202-10. 2001
    ..Therefore, it may provide useful information for clinicians to determine the appropriate therapy for each type of lymphoma...
  3. ncbi Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Br J Haematol 123:621-30. 2003
    ..The nm23-H1 protein can be an important prognostic factor in the lymphomas studied here. New treatments that target nm23 overexpression could be developed as a result of nm23-HI production by lymphoma cells...
  4. ncbi Primary gastric T-cell lymphoma not associated with human T-lymphotropic virus type I: a case report and review of the literature
    N Niitsu
    Department of Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Ann Hematol 82:197-202. 2003
    ..A review of patients with PGTL in the literature revealed a few long-term survivors, and the investigation of therapeutic strategies for PGTL is, therefore, necessary...
  5. ncbi Ovarian follicular lymphoma: a case report and review of the literature
    Nozomi Niitsu
    Department of Internal Medicine IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa, 228 8555, Japan
    Ann Hematol 81:654-8. 2002
    ..Since the prognosis for primary ovarian lymphoma is relatively favorable in many cases, it is important to establish therapeutic methods for the cure of this disease using chemotherapy and radiotherapy without radical surgery...
  6. ncbi The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukem
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Exp Hematol 30:1273-82. 2002
    ..Late-phase toxicities, such as cardiotoxicity and secondary carcinogenesis, are becoming clinically important. Therefore, we must identify the most suitable chemotherapeutic agents for the treatment of APL...
  7. ncbi Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-gamma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa 228 8555, Japan
    Leuk Res 26:745-55. 2002
    ....
  8. ncbi Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Eur J Haematol 68:91-100. 2002
    ..Therefore, a combination of VEGF and IL-6 represents a useful prognostic factor for aggressive lymphoma...
  9. ncbi High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine, Internal Medicin IV, Kitasato University School of Medicine, 1 15 1 Kitasato, Sagamihara shi, Kanagawa 228 8555, Japan
    Leuk Res 26:241-8. 2002
    ..the results of a multivariate analysis showed that the five IPI prognostic factors and the sCD44 level were independent prognostic factors, thus suggesting that sCD44 levels could be a useful prognostic marker for aggressive lymphoma..
  10. ncbi Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin's lymphoma in elderly patients: a prospective study
    N Niitsu
    Department of Hematology and Internal Medicine IV, School of Medicine, Kitasato University, Japan
    Ann Hematol 80:602-6. 2001
    ..Consequently, a new therapeutic strategy needs to be established, particularly for patients with high-intermediate or high risk...
  11. ncbi Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study
    N Niitsu
    First Department of Internal Medicine, Toho University School of Medicine, Japan
    Ann Hematol 80:411-6. 2001
    ..In addition, this regimen can be used on an outpatient basis. This combination should be tested further to determine the optimum doses and administration schedule...
  12. ncbi Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Clin Cancer Res 10:4077-82. 2004
    ..Granulocyte colony-stimulating factor (G-CSF) enhances the cytotoxicity of neutrophils through ADCC, and it can be speculated that a combination of rituximab and G-CSF may augment the treatment efficacy of rituximab...
  13. doi Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan
    Hematol Oncol 28:68-74. 2010
    ..Grade 4 neutropenia was observed in 91 patients and thrombocytopenia in 9 patients. The addition of rituximab to CyclOBEAP therapy may enhance the effect of CyclOBEAP therapy for DLBCL...
  14. doi A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397 1 Yamane, Hidaka, Saitama, 350 1298, Japan
    Ann Hematol 90:185-92. 2011
    ..These results suggest an important role for nm23-H1 in malignant progression and a potential therapeutic target for DLBCL...
  15. ncbi Multicenter Phase II study of CyclOBEAP regimen for elderly patients with poor-prognosis aggressive lymphoma
    Nozomi Niitsu
    Department of Internal Medicine, Hematology Division, Saitama Medical University, Iruma gun, Saitama, Japan
    Hematol Oncol 24:220-6. 2006
    ..We showed that the CyclOBEAP regimen can be safely used in the treatment of aggressive lymphoma in elderly patients and it achieved a high rate of remission...
  16. ncbi Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma
    Nozomi Niitsu
    Hematology Division, Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma gun, Saitama, Japan
    Leuk Lymphoma 47:1908-14. 2006
    ..However, a long-term risk of the BEACOPP regimen is the development of secondary leukemia or myelodysplastic syndrome. Therefore, long-term follow-up of these patients, including monitoring for toxicities, is necessary...
  17. doi Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL
    Yuhko Suzuki
    Department of Hematology, Kitasato University School of Medicine, 1 15 1 Kitasato, Minami Ku, Sagamihara, 252 0374, Japan
    Ann Hematol 91:997-1005. 2012
    ..3, 95% CI: 1.49-35.8, p = 0.04) compared to patients who were CD20 normal. Our findings indicate that the CD20 level (FCM) at onset is an independent predictor of the prognosis of patients with DLBCL...
  18. ncbi Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma
    Nozomi Niitsu
    Hematology Division Department of Internal Medicine, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama, Japan
    Ann Hematol 85:374-80. 2006
    ..The addition of etoposide and bleomycin to CHOP therapy may enhance the effect of CHOP therapy for aggressive lymphoma. We will perform a prospective study of CyclOBEAP regimen combined with rituximab and test its safety and efficacy...
  19. ncbi Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma
    Nozomi Niitsu
    Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Clin Cancer Res 10:2482-90. 2004
    ..Recently, we established an ELISA technique for measuring nm23-H1 protein in serum and found that the serum nm23-H1 level is a potential prognostic factor for patients with non-Hodgkin's lymphoma...
  20. ncbi [Successful radiotherapy for the thoracic cord infiltration of adult T-cell leukemia/lymphoma]
    Nobu Akiyama
    Department of Internal Medicine IV, Section of Hematology, School of Medicine, Kitasato University
    Rinsho Ketsueki 44:1095-100. 2003
    ..Administration of intrathecal methotrexate and prednisolone, systemic dexamethasone and local irradiation of 30 Gy improved the paralysis and the abnormal MRCT findings. Rehabilitation restored the patient's ability to walk...
  21. ncbi Prognostic impact of chromosomal alteration of 3q27 on nodal B-cell lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 329 consecutive patients
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan
    Leuk Res 31:1191-7. 2007
    ..PFS rate was significantly higher in the DLBCL patients with 3q27 translocation than in those with 18q21 translocation. These findings suggest that the presence of 3q27 translocation is a significant prognostic factor in DLBCL...
  22. ncbi Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan
    Cancer Sci 98:109-12. 2007
    ..In addition, it was effective in patients who had previously been treated with doxorubicin and good treatment results were obtained in elderly patients with relapsed PTCL...
  23. doi Lymphoproliferative disorders after immunosuppressive therapy for aplastic anemia: a case report and literature review
    Yuhko Suzuki
    Department of Hematology, School of Medicine, Kitasato University, Sagamihara, Japan
    Acta Haematol 121:21-6. 2009
    ..We report DLBCL after immunosuppressive therapy for AA. Although this is a rare complication, it should be considered before beginning immunosuppressive therapy...
  24. ncbi t(6;14)(q15;q32) in a patient with CD5+CD10+ diffuse large B-cell lymphoma
    Miyuki Hayama
    Department of Hematology, Kitasato University, Sagamihara shi, Kanagawa, Japan
    Int J Hematol 86:147-9. 2007
    ..Regarding CD5+CD10+ diffuse large B-cell lymphoma with a non-random chromosomal translocation of t(6;14)(q15;q32), studies on the mechanism of lymphomagenesis are needed...
  25. doi Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy
    Nozomi Niitsu
    Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan
    J Clin Oncol 28:5097-100. 2010
    ..In this prospective study, the frequency of and risk factors for HBV reactivation in patients who were receiving rituximab chemotherapy were examined...
  26. ncbi Granulocytic differentiation of leukemic cells with t(9;11)(p22;q23) induced by all-trans-retinoic acid
    Kimiko Iijima
    First Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
    Leuk Lymphoma 45:1017-24. 2004
    ..Pretreatment with TSA before exposure to ATRA displayed increased effect. Based on these findings, combined treatment with ATRA and TSA may be clinically useful in therapy for acute leukemia displaying MLL-AF9 fusion gene...
  27. ncbi t(8;14)(q24;q32) in two patients with CD10-negative primary thyroid diffuse large B-cell lymphoma
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma gun, Saitama, Japan
    Leuk Res 31:707-11. 2007
    ....
  28. ncbi Development of hepatosplenic gammadelta T-cell lymphoma with pancytopenia during early pregnancy: a case report and review of the literature
    Nozomi Niitsu
    Department of Internal Medicine IV, Kitasato University School of Medicine, Kanagawa, Japan
    Eur J Haematol 73:367-71. 2004
    ..Pregnancy-associated lymphoma is resistant to standard chemotherapy and is associated with poor prognosis. Therefore, it is important to accumulate clinicopathologic data of such cases for the development of a treatment modality...
  29. doi Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan
    Leuk Res 32:1837-41. 2008
    ..The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state...
  30. doi Ellagic acid, a natural polyphenolic compound, induces apoptosis and potentiates retinoic acid-induced differentiation of human leukemia HL-60 cells
    Yuki Hagiwara
    Research Institute for Clinical Oncology, Saitama Cancer Center, 818 Komuro, Ina machi, Kitaadachi gun, Saitama, Japan
    Int J Hematol 92:136-43. 2010
    ..These results indicate that EA is a potent apoptosis inducer and also effectively potentiates ATRA-induced myeloid differentiation of HL-60 cells...
  31. doi Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
    Hematol Oncol 26:152-8. 2008
    ..PTCL-U is a heterogeneous disease with regard to histological type and pathological state. Because PTCL-U is generally not responsive to CHOP therapy, new treatment strategies need to be developed...
  32. doi Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate
    Nozomi Niitsu
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
    Cancer Sci 101:1309-13. 2010
    ..Germinal center B-cell type and EBER-positive patients tended to show spontaneous remission. The utility of rituximab should be examined in future studies...
  33. doi Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma, not otherwise specified
    Nozomi Niitsu
    Department of Hematology, International Medical Center, Saitama Medical University, Saitama, Japan
    Clin Cancer Res 17:2893-9. 2011
    ..We examined whether nm23-H1 is a prognostic factor of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)...
  34. ncbi CD3- and CD4-positive plasmablastic lymphoma: a literature review of Japanese plasmablastic lymphoma cases
    Yuhko Suzuki
    Department of Hematology, Kitasato University School of Medicine, Sagamihara, Japan
    Intern Med 49:1801-5. 2010
    ..He was diagnosed as a plasmablastic lymphoma; radiation therapy (RT) was started, but the response to the RT was only a partial response. To our knowledge, this is the first report of a patient with PBL expressing CD3 and CD4...
  35. ncbi Alveolar rhabdomyosarcoma mimicking nasal lymphoma at the initial presentation
    Tatsuya Ihara
    Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan
    J Clin Exp Hematop 48:61-4. 2008
    ..We conclude that rhabdomyosarcoma should be included in the differential diagnoses of CD56(+) small round cell tumor, and immunohistochemical and cytogenetic studies should be performed...
  36. doi Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
    Ken Ohmachi
    Yokohama City University Hospital, Kanagawa, Japan
    J Clin Oncol 31:2103-9. 2013
    ..The present phase II study assessed the efficacy and safety of bendamustine plus rituximab (BR) in this population...
  37. ncbi [Granulocytic sarcoma of the colon in chronic myelomonocytic leukemia]
    Nobu Akiyama
    Kitasato University, School of Medicine, Department of Internal Medicine IV, Section of Hematology
    Rinsho Ketsueki 43:937-42. 2002
    ..At present, nine cases of GS in the colon have been reported. However, these cases did not include CMML. This is the first report describing GS in the colon associated with CMML...
  38. doi Current treatment strategy of diffuse large B-cell lymphomas
    Nozomi Niitsu
    Department of Hematology, Saitama Medical University, Hidaka, Saitama, Japan
    Int J Hematol 92:231-7. 2010
    ..For young, high-risk DLBCL patients, treatment that incorporates rituximab and hematopoietic stem cell transplantation has been administered in clinical studies...
  39. doi The GAS5 (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of t(1;3)(q25;q27) in a patient with B-cell lymphoma
    Yuichi Nakamura
    Department of Hematology, Saitama Medical University, 38 Morohongo, Moroyama machi, Iruma gun, Saitama 350 0495, Japan
    Cancer Genet Cytogenet 182:144-9. 2008
    ..The GAS5 gene on chromosome 1q25 is the second BCL6 partner, to the SNHG5 on 6q15, which is classified as a non-protein-coding multiple snoRNA host and 5'-TOP class gene...
  40. ncbi Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma
    Tadashi Yoshino
    Department of Pathology, Okayama University Graduate School of Medicine and Dentistry, Okayama 700 8558, Japan
    Br J Haematol 118:482-7. 2002
    ..In conclusion, the present findings established that CLA is an independent and important prognostic factor in patients with NK-cell lymphomas...
  41. ncbi [Clinical significance of biological prognostic factors in non-Hodgkin lymphoma: analysis of serum and cell surface nm 23-H1 protein]
    Nozomi Niitsu
    Rinsho Ketsueki 44:211-8. 2003
  42. ncbi Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma
    Nozomi Niitsu
    Hematology Division Department of Internal Medicine, Saitama Medical University, 38 Morohongo, Saitama 350 0495, Japan
    Cancer Sci 97:933-7. 2006
    ..The R-CMD regimen was safe in elderly patients with DLBCL. No new signs of cardiotoxicity were observed with this regimen. It was also effective in patients with relapsed or refractory DLBCL who had previously used DXR...
  43. ncbi Prognostic factors in diffuse large B-cell lymphoma
    Nozomi Niitsu
    Intern Med 45:227-8. 2006
  44. ncbi [The stratification treatment that was based on a prognostic factor of malignant lymphoma]
    Nozomi Niitsu
    Division of Hematology, Department of Internal Medicine, Saitama Medical University
    Nihon Rinsho 65:534-9. 2007
  45. ncbi The t(1;3)(p34;q27) translocation: a nonrandom BCL6 rearrangement in diffuse large B cell lymphoma
    Nozomi Niitsu
    Ann Hematol 87:151-3. 2008
  46. doi Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan
    Kazuyuki Shimada
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, 65 Tsurumai Cho, Showa Ku, Nagoya 466 8550 Japan
    J Clin Oncol 26:3189-95. 2008
    ..To evaluate the safety and efficacy of rituximab-containing chemotherapies for intravascular large B-cell lymphoma (IVLBCL)...
  47. ncbi Lymphoid neoplasms associated with mosquito bites
    Naoki Wakimoto
    Intern Med 44:1118-9. 2005
  48. ncbi Primary pulmonary plasmacytoma involving bilateral lungs and marked hypergammaglobulinemia: differentiation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
    Nozomi Niitsu
    Department of Hematology, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama 350 0495, Japan
    Leuk Res 29:1361-4. 2005
    ..The effectiveness of the chemotherapy could confirm our diagnosis, although MALT-type lymphoma with plasmacytic differentiation cannot be completely ruled out...
  49. ncbi Treatment for gastric mucosa-associated lymphoid tissue (MALT) lymphoma
    Tomoya Maeda
    Intern Med 45:353-4. 2006